Cita APA

Harding, J. J., Tan, D. S. W., Bedard, P. L., Rodon Ahnert, J., Doi, T., & Bauer, T. (2018). Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor.

Citación estilo Chicago

Harding, James J., Daniel S. W. Tan, Philippe L. Bedard, Jordi Rodon Ahnert, Toshihiko Doi, y Todd Bauer. Characterization and Phase I Study of CLR457, an Orally Bioavailable Pan-class I PI3-kinase Inhibitor. 2018.

Cita MLA

Harding, James J., et al. Characterization and Phase I Study of CLR457, an Orally Bioavailable Pan-class I PI3-kinase Inhibitor. 2018.